201609-38-3

Basic information

• Product Name: 4-METHOXY-4-PHENYLPIPERIDINE
• Synonyms: 4-METHOXY-4-PHENYLPIPERIDINE
• CAS NO: 201609-38-3
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.26948
• Mol File: 201609-38-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-METHOXY-4-PHENYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-4-PHENYLPIPERIDINE(201609-38-3)
• EPA Substance Registry System: 4-METHOXY-4-PHENYLPIPERIDINE(201609-38-3)

Safety Data

• Hazardous Substances Data: 201609-38-3(Hazardous Substances Data)

Upstream product

• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 201609-37-2 4-methoxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 201608-95-9 2a-[4-(4-methoxy-4-phenyl-piperidyl)butyl]-2a,3,4,5-tetrahydrobenz[cd]indole-2(1H)-one 

Relevant articles and documents

Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein

P-glycoprotein (P-gp) is an ATP-dependent efflux pump that has a marked impact on the absorption, distribution, and excretion of therapeutic drugs. As P-gp inhibition can result in drug–drug interactions and altered drug bioavailability, identifying molec

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Cyclic hexapeptides having antibiotic activity

This invention relates to new polypeptide compound represented by general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

Tetrahydrobenzindole compounds

A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4and R5and n are as defined in the specification.